Evidence map›Paper›PMID 40322492›Full record

ArticleEuropean heart journal. Case reports2025

Case report on heart transplantation in endomyocardial fibrosis: 'do not let your guard down'-suspicion of disease recurrence after heart transplantation.

Lorena Herrador, Jara Gayán-Ordás, Roger Llatjós, Eduard Claver-Garrido, José González-Costello

Abstract readCase Reports
In one paragraph

Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lorena HerradorDepartment of Cardiology, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID https://orcid.org/0000-0002-3196-4975
Jara Gayán-OrdásDepartment of Cardiology, Hospital Universitari Arnau de Vilanova, Av. Alcalde Rovira Roure, 80, 25198 Lleida, Spain.
Roger LlatjósDepartment of Pathology, Hospital Universitari de Bellvitge -IDIBELL, C/Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Eduard Claver-GarridoDepartment of Cardiology, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.
José González-CostelloDepartment of Cardiology, Hospital Universitari de Bellvitge, C/Feixa Llarga s/n, 08907, L'Hospitalet de Llobregat, Barcelona, Spain.ORCID https://orcid.org/0000-0002-7437-3630

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Endomyocardial fibrosis (EMF) is a challenging disease that leads to severe heart failure (HF) due to progressive fibrosis. Diet, parasitic infections, autoimmune disorders, and genetic predisposition have been advocated in EMF pathogenesis, and treatment options for EMF are limited with scarce evidence supporting heart transplantation (HTx). Case summary: A 38-year-old man was diagnosed with EMF with biventricular involvement. The diagnostic work-up ruled out eosinophilia, infections, and autoimmune conditions. The patient rapidly deteriorated, leading to cardiogenic shock with multiorgan failure, and an emergency HTx was performed. Three months later, the graft developed biventricular hypertrophy with atrial fibrosis and the endomyocardial biopsy (EMB) showed extensive inflammation and myocardial damage, compatible with Grade 2R (G3a) cellular rejection. After steroid pulses, the follow-up EMB reveals subendocardial fibrosis and microcalcifications, suggesting the possibility of an EMF recurrence. Nevertheless, the patient had a good clinical outcome, remaining asymptomatic with good graft function 2 years after the transplant. Discussion: This is the first reported case of suspected EMF recurrence following HTx. Given the unknown pathogenesis of EMF, close monitoring is crucial, though HTx appears to be a viable and successful treatment option for these patients.

Indexed as

Case reportEndomyocardial biopsyEndomyocardial fibrosisHeart failureHeart transplantation

Identifiers

PMID40322492
PMCPMC12046388

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.